ATYR aTyr Pharma, Inc.

NASDAQ
$0.56

aTyr Pharma, Inc. (ATYR) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.6% since its last earnings release on August 7, 2026.

aTyr Pharma Beat Consensus Estimates
Friday, August 7, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · After Close
Earnings Whisper
-
vs ($0.11)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.55

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About aTyr Pharma, Inc.

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow